More specifically, tumor-bearing mice treated neoadjuvant therapy of CBDCA combined with anti-PD-1 antibodies showed a survival rate between 50 and 90% across all three models, which were significantly higher than those treated with single-drug regimens or CTRL (Supplemental Tables 10–12, p < 0.0001). The gene discussed is PDCD1; the disease is neoplasm.